Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,316
  • Shares Outstanding, K 6,349
  • Annual Sales, $ 710 K
  • Annual Income, $ -21,410 K
  • 60-Month Beta 0.43
  • Price/Sales 53.26
  • Price/Cash Flow N/A
  • Price/Book 2.14
Trade LGVN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.53
  • Number of Estimates 2
  • High Estimate -0.51
  • Low Estimate -0.55
  • Prior Year -2.80
  • Growth Rate Est. (year over year) +81.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +16.03%
on 08/20/24
4.29 -40.09%
on 07/29/24
-0.34 (-11.68%)
since 07/23/24
3-Month
0.77 +233.46%
on 06/11/24
6.40 -59.84%
on 07/10/24
+1.45 (+129.46%)
since 05/23/24
52-Week
0.77 +233.46%
on 06/11/24
35.60 -92.78%
on 08/31/23
-24.83 (-90.62%)
since 08/23/23

Most Recent Stories

More News
Stocks Set to Open Higher as Investors Await U.S. Jobs Data and Big Tech Earnings, Fed Meeting on Tap

September S&P 500 E-Mini futures (ESU24) are up +0.29%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.38% this morning as market participants looked ahead to earnings reports from major tech...

ESU24 : 5,652.50s (+1.05%)
NQU24 : 19,790.75s (+1.09%)
MMM : 130.55 (+1.52%)
CHTR : 348.73 (+2.47%)
DECK : 974.56 (+2.06%)
DXCM : 74.07 (+2.48%)
MSFT : 416.79 (+0.30%)
AMZN : 177.04 (+0.52%)
META : 528.00 (-0.74%)
AAPL : 226.84 (+1.03%)
SBUX : 94.02 (+1.72%)
MCD : 289.52 (+0.11%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

ATNM : 2.01 (-1.47%)
BPTH : 1.2000 (-5.51%)
LGVN : 2.57 (-2.28%)
SLS : 1.3200 (+0.76%)
BMY : 48.11 (+1.03%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

ATNM : 2.01 (-1.47%)
BPTH : 1.2000 (-5.51%)
LGVN : 2.57 (-2.28%)
SLS : 1.3200 (+0.76%)
BMY : 48.11 (+1.03%)
Longeveron (NASDAQ: LGVN) Schedules Release of Q1 2024 Financial Results, Earnings Conference Call

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.57 (-2.28%)
Longeveron (NASDAQ: LGVN) to Participate in Upcoming Planet MicroCap Showcase

Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, will be presenting at next month’s Planet MicroCap Showcase. The conference is slated for May 1–2,...

LGVN : 2.57 (-2.28%)
Longeveron (NASDAQ: LGVN) Closes on Warrant Exercise Offering, Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.57 (-2.28%)
Longeveron (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M

Longeveron (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.57 (-2.28%)
Longeveron (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.57 (-2.28%)
Longeveron (NASDAQ: LGVN) Releases Pricing for Mulitmillion-Dollar Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.57 (-2.28%)
Longeveron (NASDAQ: LGVN) Discusses 2023 Progress, 2024 Plans in Corporate Update

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for...

LGVN : 2.57 (-2.28%)

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 2.78
2nd Resistance Point 2.72
1st Resistance Point 2.65
Last Price 2.57
1st Support Level 2.52
2nd Support Level 2.46
3rd Support Level 2.39

See More

52-Week High 35.60
Fibonacci 61.8% 22.30
Fibonacci 50% 18.19
Fibonacci 38.2% 14.08
Last Price 2.57
52-Week Low 0.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar